Prana Biotechnology is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.

Prana Biotechnology will be presenting at the China Healthcare Investment & Partnering Symposium on Saturday 17 March 2018 at 9.30am China Standard Time.   Please access the webcast via the following link: http://wsw.com/webcast/brileyco20/pran/ The webcast will be archived for 90 days following the presentation.

Dr. David Stamler will be presenting at the China Healthcare Investment & Partnering Symposium on Saturday 17 March 2018 at 9.30am China Standard Time.

Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration

Prana Biotechnology JPM investor presentation_updated

Dr. David Stamler presenting at Biotech Showcase

Prana has today announced that is has received a A$3.02 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.

AGM Presentation 2017

Prana Biotechnology invites investors unable to attend the Annual General Meeting to participate via teleconference.

Prana has announced that it has filed its Annual Report on Form 20-F